William S. Dalton | Academic Influence

William S. Dalton's AcademicInfluence.com Rankings

William S. Dalton

Philosophy

#5729

World Rank

#8616

Historical Rank

Logic

#3365

World Rank

#4512

Historical Rank

philosophy Degrees

Download Badge

Philosophy

William S. Dalton's Degrees

Doctorate Medicine University of Colorado
PhD Pharmacology University of Colorado

Why Is William S. Dalton Influential?

(Suggest an Edit or Addition)

According to Wikipedia, William S. Dalton is an American physician and oncologist, who is board certified in internal medicine and oncology. Since 2002 he has been the President, CEO, and Center Director of the H. Lee Moffitt Cancer Center and Research Institute at the University of South Florida . He served as dean of the University of Arizona College of Medicine, 2001–2002.

(See a Problem?)

William S. Dalton's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group (2003) (2143)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. (2005) (1965)
Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. (1999) (1730)
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. (1997) (1301)
Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells (2004) (1141)
Environment-mediated drug resistance: a major contributor to minimal residual disease (2009) (743)
MicroRNA-155 Is Regulated by the Transforming Growth Factor β/Smad Pathway and Contributes to Epithelial Cell Plasticity by Targeting RhoA (2008) (677)
Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. (1989) (561)
Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. (1993) (525)
Cell Adhesion Mediated Drug Resistance (CAM-DR): Role of Integrins and Resistance to Apoptosis in Human Myeloma Cell Lines (1999) (518)
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. (2007) (515)
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. (2006) (511)
The Bone Marrow Microenvironment as a Tumor Sanctuary and Contributor to Drug Resistance (2008) (495)
Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. (1999) (443)
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. (1996) (432)
P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. (1991) (393)
Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. (1999) (367)
Adhesion to fibronectin via β1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR) (2000) (365)
P-glycoprotein expression and function in circulating blood cells from normal volunteers. (1994) (365)
microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. (2010) (345)
Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. (1999) (327)
Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. (1986) (309)
Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. (1993) (304)
A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study. (2017) (294)
Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. (2001) (283)
The proteasome. (2004) (278)
Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. (2004) (269)
Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas. (2012) (265)
Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms (2003) (257)
Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. (2000) (250)
Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. (1996) (250)
Vaults Are Up-regulated in Multidrug-resistant Cancer Cell Lines* (1998) (238)
Methylation of discrete regions of the O6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene (1997) (232)
Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. (1991) (229)
Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein staining. (1989) (218)
Cancer BiomarkersAn Invitation to the Table (2006) (207)
Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. (1998) (206)
Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death (2003) (204)
Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy. (2008) (195)
Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-κB (RelB/p50) in myeloma cells (2003) (190)
Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration. (1991) (185)
Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines. (2000) (182)
Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. (2009) (180)
STAT proteins as novel targets for cancer therapy. Signal transducer an activator of transcription. (1999) (180)
Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF7 human breast cancer cell line. (1991) (176)
ABCG2 expression, function, and promoter methylation in human multiple myeloma. (2006) (172)
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. (2009) (164)
Selection for drug resistance results in resistance to Fas-mediated apoptosis. (1997) (162)
Integrin-Mediated Drug Resistance in Multiple Myeloma (2000) (159)
Mechanisms Associated with cell Adhesion Mediated Drug Resistance (CAM-DR) in Hematopoietic Malignancies (2004) (157)
Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines. (1988) (156)
Identification of cryptic sites of DNA sequence amplification in human breast cancer by chromosome microdissection (1994) (155)
A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A southwest oncology group study (1995) (153)
Inhibition of Bcr–Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells (2002) (152)
Multidrug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-glycoprotein overexpression. (1989) (148)
pH and drug resistance. I. Functional expression of plasmalemmal V-type H+-ATPase in drug-resistant human breast carcinoma cell lines. (1999) (148)
Reduction in drug-induced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells. (2001) (147)
Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. (2003) (139)
Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest. (2001) (138)
Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation. (1989) (136)
Tumor microenvironment and drug resistance in hematologic malignancies. (2006) (133)
Development and characterization of a melphalan-resistant human multiple myeloma cell line. (1991) (131)
Cell adhesion is a key determinant in de novo multidrug resistance (MDR): new targets for the prevention of acquired MDR. (2001) (131)
Stat3 Activity in Melanoma Cells Affects Migration of Immune Effector Cells and Nitric Oxide-Mediated Antitumor Effects1 (2005) (130)
Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line. (1999) (129)
P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. (1993) (127)
The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells. (2005) (127)
Adhesion-Mediated Intracellular Redistribution of c-Fas-Associated Death Domain-Like IL-1-Converting Enzyme-Like Inhibitory Protein-Long Confers Resistance to CD95-Induced Apoptosis in Hematopoietic Cancer Cell Lines1 (2002) (126)
Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation. (1995) (126)
Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. (2004) (123)
Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. (2004) (123)
Immunohistochemical detection and quantitation of p-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation (1989) (122)
Implementing personalized medicine in a cancer center. (2011) (122)
Dysregulation of CD95/CD95 ligand-apoptotic pathway in CD3(+) large granular lymphocyte leukemia. (1998) (119)
Optimizing Cancer Treatment Using Game Theory: A Review (2019) (114)
Phase III study of PSC‐833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95) (2006) (111)
Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma (2017) (110)
Tipifarnib and Bortezomib Are Synergistic and Overcome Cell Adhesion–Mediated Drug Resistance in Multiple Myeloma and Acute Myeloid Leukemia (2006) (108)
Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas. (2006) (108)
Verapamil reversal of doxorubicin resistance in multidrug-resistant human myeloma cells and association with drug accumulation and DNA damage. (1988) (107)
Analysis of multidrug resistance-associated protein (MRP) messenger RNA in normal and malignant hematopoietic cells. (1994) (104)
The tumor microenvironment as a determinant of cancer cell survival: a possible mechanism for de novo drug resistance (2000) (102)
Proteomic Contributions to Personalized Cancer Care* (2008) (102)
Reversal of drug‐resistance in multiple myeloma with verapamil (1988) (101)
Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma. (2009) (100)
Dysregulation of CD95/CD95 ligand-apoptotic pathway in CD3+ large granular lymphocyte leukemia (1998) (100)
P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy (1993) (99)
Expression of the human NRAMP1 gene in professional primary phagocytes: studies in blood cells and in HL‐60 promyelocytic leukemia (1997) (97)
Synergistic inhibition by verapamil and quinine of P-glycoprotein-mediated multidrug resistance in a human myeloma cell line model. (1991) (92)
Clonal chromosome abnormalities in human breast carcinomas I. Twenty‐eight cases with primary disease (1993) (92)
Follicular dendritic cell-dependent drug resistance of non-Hodgkin lymphoma involves cell adhesion-mediated Bim down-regulation through induction of microRNA-181a. (2010) (91)
The tumor microenvironment: focus on myeloma. (2003) (86)
The tumor microenvironment shapes hallmarks of mature B-cell malignancies (2015) (84)
The tumor microenvironment as a determinant of drug response and resistance. (1999) (84)
Cell adhesion to fibronectin (CAM-DR) influences acquired mitoxantrone resistance in U937 cells. (2006) (83)
Quantitative polymerase chain reaction analysis of mdr1 mRNA in multiple myeloma cell lines and clinical specimens. (1993) (81)
P-glycoprotein-mediated multidrug resistance in tumor cells: biochemistry, clinical relevance and modulation. (1995) (80)
Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia. (2001) (79)
Analysis of MRP mRNA in mitoxantrone-selected, multidrug-resistant human tumor cells. (1994) (77)
Mechanisms of drug resistance in hematologic malignancies. (1997) (77)
Expression of cytokeratin confers multiple drug resistance. (1994) (76)
Stemness of B-cell Progenitors in Multiple Myeloma Bone Marrow (2012) (74)
Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone. (2012) (74)
Clonal chromosome abnormalities in human breast carcinomas II. Thirty‐four cases with metastatic disease (1993) (74)
Farnesyltransferase inhibitor FTI‐R115777 is well tolerat ed, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma (2003) (73)
The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells (2003) (71)
Cytogenetic and phenotypic analysis of a human colon carcinoma cell line resistant to mitoxantrone. (1988) (71)
A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours (2014) (70)
Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors (2016) (70)
Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918. (1996) (69)
Myeloma cells selected for resistance to CD95-mediated apoptosis are not cross-resistant to cytotoxic drugs: evidence for independent mechanisms of caspase activation. (1999) (66)
A microenvironment-mediated c-Myc/miR-548m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas. (2013) (65)
Lung resistance-related protein: determining its role in multidrug resistance. (1999) (64)
Pharmacokinetics of n‐4‐hydroxyphenyl‐retinamide and the effect of its oral administration on plasma retinol concentrations in cancer patients (1989) (64)
Verapamil suppresses the emergence of P‐glycoprotein‐mediated multi‐drug resistance (1996) (64)
Collaborative Biomedicine in the Age of Big Data: The Case of Cancer (2014) (62)
Establishment of two new cell lines derived from human breast carcinomas with HER-2/neu amplification. (1991) (61)
Frequency, Characteristics, and Reversibility of Peripheral Neuropathy (PN) in the APEX Trial. (2005) (61)
HSP70 inhibition reverses cell adhesion mediated and acquired drug resistance in multiple myeloma (2008) (61)
Multiple Myeloma: New Insights and Therapeutic Approaches. (2000) (59)
Bone Marrow Stroma Confers Resistance to Apo2 Ligand/TRAIL in Multiple Myeloma in Part by Regulating c-FLIP1 (2008) (59)
Combination therapy with AG-490 and interleukin 12 achieves greater antitumor effects than either agent alone. (2002) (56)
The clinical relevance of multidrug resistance. (1990) (55)
Phase I study of busulfan and cyclophosphamide in preparation for allogeneic marrow transplant for patients with multiple myeloma. (1992) (55)
A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in cancer (2011) (55)
PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas (2018) (52)
Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells. (2005) (50)
Broadened clinical utility of gene gun-mediated, granulocyte-macrophage colony-stimulating factor cDNA-based tumor cell vaccines as demonstrated with a mouse myeloma model. (1998) (49)
Inhibition of JAK kinase activity enhances Fas-mediated apoptosis but reduces cytotoxic activity of topoisomerase II inhibitors in U266 myeloma cells. (2001) (49)
Significance of Fas and Retinoblastoma Protein Expression During the Progression of Barrett’s Metaplasia to Adenocarcinoma (1999) (49)
Drug resistance in multiple myeloma: approaches to circumvention. (1999) (48)
Pharmacology of mitoxantrone: mode of action and pharmacokinetics (2004) (47)
HYD1-induced increase in reactive oxygen species leads to autophagy and necrotic cell death in multiple myeloma cells (2009) (46)
Evidence for cytoplasmic P-glycoprotein location associated with increased multidrug resistance and resistance to chemosensitizers. (1996) (45)
An Ex Vivo Platform for the Prediction of Clinical Response in Multiple Myeloma. (2017) (45)
Drug resistance and drug development in multiple myeloma. (2002) (44)
BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models. (2019) (44)
A Protective Role for the Human SMG-1 Kinase against Tumor Necrosis Factor-α-induced Apoptosis* (2008) (44)
Characterization of a R115777-Resistant Human Multiple Myeloma Cell Line with Cross-Resistance to PS-341 (2005) (43)
Mitomycin C resistant L1210 leukemia cells: association with pleiotropic drug resistance. (1987) (42)
Environmental-mediated drug resistance: a target for multiple myeloma therapy (2009) (41)
Cytokine-based tumor cell vaccine is equally effective against parental and isogenic multidrug-resistant myeloma cells: the role of cytotoxic T lymphocytes. (1999) (40)
Resistance to the chemosensitizer verapamil in a multi‐drug‐resistant (MDR) human multiple myeloma cell line (1996) (39)
Reversal of multidrug resistance to cancer chemotherapy (1993) (39)
An in vivo model of human multidrug-resistant multiple myeloma in SCID mice. (1993) (39)
Bortezomib vs. dexamethasone in relapsed multiple myeloma: A phase 3 randomized study. (2004) (38)
Phase II study of Fenretinide (N-[4-Hydroxyphenyl]retinamide) in advanced breast cancer and melanoma (1990) (38)
Combined Inhibition of Notch Signaling and Bcl-2/Bcl-xL Results in Synergistic Antimyeloma Effect (2010) (38)
The cytoplasmic trafficking of DNA topoisomerase IIalpha correlates with etoposide resistance in human myeloma cells. (2004) (38)
Role of glutathione and its associated enzymes in multidrug-resistant human myeloma cells. (1989) (38)
A Novel TNF Receptor-Associated Factor 6 Binding Domain Mediates NF-κB Signaling by the Common Cytokine Receptor β Subunit (2010) (38)
Does lowering cholesterol cause cancer? (1996) (37)
Targeting the bone marrow microenvironment in hematologic malignancies. (2004) (36)
Direct relation of DNA lesions in multidrug-resistant human myeloma cells to intracellular doxorubicin concentration. (1988) (36)
Cytokeratin expression results in a drug-resistant phenotype to six different chemotherapeutic agents. (1996) (36)
Relevance of multidrug resistance to rheumatoid arthritis: development of a new therapeutic hypothesis. (1996) (36)
Bortezomib Continues Demonstrates Superior Efficacy Compared with High-Dose Dexamethasone in Relapsed Multiple Myeloma: Updated Results of the APEX Trail. (2005) (35)
Targeting the mitochondria: an exciting new approach to myeloma therapy. Commentary re: N. J. Bahlis et al., Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin. Can (2002) (34)
Monitoring a Nuclear Factor-κB Signature of Drug Resistance in Multiple Myeloma* (2011) (33)
AACR Cancer Progress Report 2012 (2012) (33)
Effects of tumor necrosis factor on sensitive and multidrug resistant human leukemia and myeloma cell lines. (1989) (33)
Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer (2003) (32)
Effects of ethanol and paraformaldehyde on RNA yield and quality. (1994) (32)
Combination chemotherapy with cyclophosphamide, vincristine, adriamycin, and dexamethasone (CVAD) plus oral quinine and verapamil in patients with advanced breast cancer (2004) (31)
Functional interactions between synthetic alkyl phospholipids and the ABC transporters P-glycoprotein, Ste-6, MRP, and Pgh 1. (1997) (31)
Bortezomib restores stroma‐mediated APO2L/TRAIL apoptosis resistance in multiple myeloma (2010) (30)
Multidrug resistance in the laboratory and clinic. (1994) (30)
Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease (2019) (29)
Kinome Sirna Screen Identifies SMG-1 as a Negative Regulator of Hypoxia-inducible Factor-1α in Hypoxia* (2009) (29)
On the eve of personalized medicine in oncology. (2008) (29)
Elimination of chemoresistant multiple myeloma clonogenic colony-forming cells by combined treatment with a plasma cell-reactive monoclonal antibody and a P-glycoprotein-reactive monoclonal antibody. (1989) (29)
CD95 Antigen Mutations in Hematopoietic Malignancies (2001) (28)
Gene-specific DNA interstrand cross-links produced by nitrogen mustard in the human tumor cell line Colo320HSR. (1992) (28)
A phase II trial of autologous bone marrow transplantation (ABMT) in acute leukemia with edelfosine purged bone marrow. (1996) (28)
A phase I/II trial of paclitaxel for non‐Hodgkin's lymphoma followed by paclitaxel plus quinine in drug‐resistant disease (1998) (28)
Altered expression of P‐glycoprotein and cellular adhesion molecules on human multi‐drug‐resistant tumor cells does not affect their susceptibility to NK‐ and LAK‐mediated cytotoxicity (1991) (27)
Mutations in the Fas antigen in patients with multiple myeloma (1997) (26)
17 – Cytogenetic and Molecular Biologic Alterations Associated with Anthracycline Resistance (1988) (26)
Drug resistance modulation in the laboratory and the clinic. (1993) (26)
Mutations in the Fas antigen in patients with multiple myeloma (1997) (26)
Does P-glycoprotein predict response to chemotherapy, and if so, is there a reliable way to detect it? (1991) (25)
Serum can inhibit reversal of multidrug resistance by chemosensitisers. (1996) (25)
Metoclopramide in vincristine-induced ileus. (1985) (24)
Turning the Tide Against Cancer Through Sustained Medical Innovation: The Pathway to Progress (2014) (24)
Discovery, Development, and clinical applications of bortezomib. (2004) (24)
Persistent intracellular binding of mitoxantrone in a human colon carcinoma cell line. (1989) (24)
Decreased CP-1 (NF-Y) activity results in transcriptional down-regulation of topoisomerase IIalpha in a doxorubicin-resistant variant of human multiple myeloma RPMI 8226. (1997) (23)
The major vault protein (MVP), a new multidrug resistance associated protein, is frequently expressed in multiple myeloma. (1999) (23)
Breast tissue accumulation of retinamides in a randomized short-term study of fenretinide. (2003) (23)
Bortezomib Demonstrates Superior Efficacy to High-Dose Dexamethasone in Relapsed Multiple Myeloma: Final Report of the APEX Study. (2004) (23)
Drug resistance in myeloma: mechanisms and approaches to circumvention. (1992) (22)
In vitro evaluation of chemosensitizers for clinical reversal of P-glycoprotein-associated Taxol resistance. (1993) (22)
Synopsis of a Roundtable on Validating Novel Therapeutics for Multiple Myeloma (2006) (21)
Senescence-associated-gene signature identifies genes linked to age, prognosis, and progression of human gliomas. (2014) (19)
Bortezomib salvage followed by a Phase I/II study of bortezomib plus high‐dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma (2012) (19)
Hematologic Profiles in the Phase 3 APEX Trial. (2005) (18)
Ocular toxic effects of fenretinide. (1990) (18)
Collateral sensitivity to nitrosoureas in multidrug-resistant cells selected with verapamil. (1992) (18)
Inhibition of cell-mediated cytolysis and P-glycoprotein function in natural killer cells by verapamil isomers and cyclosporine a analogs (1995) (17)
Is p‐glycoprotein a potential target for reversing clinical drug resistance? (1994) (17)
The 2010 Health Care Reform Act: A Potential Opportunity to Advance Cancer Research by Taking Cancer Personally (2010) (17)
Recommendations for patient similarity classes: results of the AMIA 2019 workshop on defining patient similarity (2020) (15)
Semi-automated PCR method for quantitating MDR1 expression. (1996) (15)
Multiple drug resistance and intermediate filaments (1996) (15)
Oral Weekly Cyclophosphamide in Combination with Pomalidomide and Dexamethasone for Relapsed and Refractory Myeloma: Report of the Dose Escalation Cohort (2012) (14)
G-protein coupled receptor 35 (GPR35) regulates the colonic epithelial cell response to enterotoxigenic Bacteroides fragilis (2021) (13)
The effect of cannabichromene on mean blood pressure, heart rate, and respiration rate responses to tetrahydrocannabinol in the anesthetized rat. (1979) (12)
Phase I Study of a Novel Taxane BMS-188797 in Adult Patients with Solid Malignancies (2005) (12)
Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomide (2014) (12)
De Novo and Acquired Resistance to Antitumor Alkylating Agents (2006) (11)
Patient Enrichment for Precision‐Based Cancer Clinical Trials: Using Prospective Cohort Surveillance as an Approach to Improve Clinical Trials (2018) (10)
Multiple myeloma. (2001) (10)
An open‐label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed myeloma (2015) (10)
SYDNEY E. SALMON, MD (2000) (10)
Expression of the MDR1 gene (P-glycoprotein) in breast cancer. (1993) (10)
MicroRNA-155 Is Regulated by TGF β / Smad Pathway and Contributes to Epithelial Cell Plasticity by Targeting RhoA (2008) (9)
Pharmacological activity of the basic fraction of marihuana whole smoke condensate alone and in combination with delta-9-tetrahydrocannabinol in mice. (1984) (9)
Alternative (non-P-glycoprotein) mechanisms of drug resistance in non-Hodgkin's lymphoma. (1997) (9)
Modification of keratin by the chemotherapeutic drug mitoxantrone. (1988) (9)
Orien (2016) (9)
The "total cancer care" concept: linking technology and health care. (2005) (9)
Response of human multiple myeloma-derived cell lines to alkyl-lysophospholipid. (1996) (9)
Melphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple Myeloma (2020) (8)
Phase II study of pegylated liposomal doxorubicin, low‐dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma (2014) (8)
Terminal transferase in leukemias by flow cytometry. (1986) (8)
Sensitive immunofluorescence detection of the expression of P-glycoprotein in malignant cells. (1997) (8)
The Proteasome Inhibitor PR-171 Inhibits Cell Growth, Induces Apoptosis, and Overcomes De Novo and Acquired Drug Resistance in Human Multiple Myeloma Cells. (2005) (8)
A sensitive multilayer immunoalkaline phosphatase method for detection of P-glycoprotein in leukemic and tumor cells in the bone marrow. (1994) (8)
The role of P-glycoprotein in drug-resistant hematologic malignancies. (1991) (8)
Personalizing Radiotherapy Prescription Dose Using Genomic Markers of Radiosensitivity and Normal Tissue Toxicity in Non-Small Cell Lung Cancer. (2019) (8)
Use of the Total Cancer Care System to Enrich Screening for CD30-Positive Solid Tumors for Patient Enrollment Into a Brentuximab Vedotin Clinical Trial: A Pilot Study to Evaluate Feasibility (2017) (7)
The phenomenon of multidrug resistance in non-Hodgkin's lymphoma. (1996) (7)
Static adhesion of cancer cells to glass surfaces coated with glycosaminoglycans. (2008) (7)
Mechanisms of drug resistance in breast cancer. (1990) (7)
The Synergistic Effect of Melphalan and XPO1 Inhibition in Pre-Clinical Models of Multiple Myeloma (2016) (7)
Synopsis of a research roundtable presented on cell signaling in myeloma: regulation of growth and apoptosis--opportunities for new drug discovery. (2002) (7)
Cytogenetics and clinical correlations in breast cancer. (1993) (7)
Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma (2021) (7)
An ET-CURE Pilot Project Supporting Undergraduate Training in Cancer Research, Emerging Technology, and Health Disparities (2012) (6)
HYD 1-induced increase in reactive oxygen species leads to autophagy and necrotic cell death in multiple myeloma cells (2009) (6)
Myc Represses miR15a/Mir-16-1 Expression through Recruitment of HDAC3 In Mantle Cell Lymphoma (2010) (6)
Expression of two multidrug resistance genes in human prostatic carcinomas. (1998) (6)
Updated Results of Phase II Study of Cyclophosphamide(Cy), Bortezomib(Bz), Pegylated Doxorubicin(DOX), and Dexamethasone(dex), (CVDD), in Patients with Newly Diagnosed Myeloma:an Effective Induction Regimen for High Risk Disease (2012) (6)
Achieving Data Liquidity in the Cancer Community: Proposal for Coalition of All Stakeholders (2012) (6)
The influence of the tumor microenvironment on drug response and drug resistance (2008) (5)
Subsequent Primary Malignancies Among Myelodysplastic Syndrome Patients Treated with or without Lenalidomide (2014) (5)
Corrigendum: Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells (2004) (5)
PLK 1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas (2018) (5)
Advances in Brief Gene Therapy with Dominant-negative Stat 3 Suppresses Growth of the Murine Melanoma B 16 Tumor in Vivo 1 (1999) (5)
β1 Integrin Adhesion Enhances IL-6 Mediated STAT3 Signaling in Multiple Myeloma Cells: Implications for Microenvironment Influence on Tumor Cell Survival and Proliferation. (2008) (4)
Adhesion of 8226 cells to fibronectin via β1 integrins upregulates P27 levels and contributes to cell adhesion mediated drug resistance (Cam-dr) (2000) (4)
Proteasome inhibition: a new pathway in cancer therapy (2003) (4)
Therapy in premenopausal women with advanced, oestrogen positive or/and progesterone positive breast cancer: surgical oophorectomy versus the LHRH analogue, Zoladex. (1989) (4)
Clinical and laboratory approaches to drug resistance (1991) (4)
Farnesyltransferase inhibitor R 115777 ( Zarnestra , Tipifarnib ) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells (2005) (4)
Reinforcement Learning to Optimize the Treatment of Multiple Myeloma (2019) (3)
An in vivo model of chemosensitization of multidrug resistant human myeloma cell line in SCID mice: 35 (1994) (3)
Next Generation XPO1 Inhibitor KPT-8602 for the Treatment of Drug-Resistant Multiple Myeloma (2015) (3)
Clinical correlations of chromosome abnormalities in human breast, melanoma and ovarian cancer: preliminary analyses of 580 patients (1995) (3)
Alternative Pathways of Cell Death to Circumvent Pleiotropic Resistance in Myeloma Cells: Role of Cytotoxic T-Lymphocytes (2000) (3)
Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide (2016) (3)
Orien: Reshaping Cancer Research & Treatment (2016) (3)
A phase i study of high-dose melphalan + topotecan + VP-16 phosphate (Mtv) Followed by autologous stem cell rescue in multiple myeloma (2000) (3)
MiR-29 MicroRNAs Regulate IGF-1R Expression and Contribute Mantle Cell Lymphoma Growth and Survival. (2009) (3)
Sequence of novel agents in multiple myeloma: an instrumental variable analysis. (2013) (2)
Carcinoma Cell Line Resistant to Mitoxantrone Cytogenetic and Phenotypic Analysis of a Human Colon Updated (2006) (2)
Phase I Study of Bortezomib, (BTZ) Followed by High-Dose Melphalan, (HD Mel) and BTZ as Conditioning Regimen for Tandem Peripheral Blood Stem Cell Transplants (TanPSCT) in Patients with Primary Refractory Multiple Myeloma (MM) and Plasma Cell Leukemia (PCL). (2007) (2)
Considerations in the management of myeloma. (2000) (2)
1-1-2012 Coordinated Silencing of MYC-Mediated miR-29 by HDAC 3 and EZH 2 as a Therapeutic Target of Histone Modification in Aggressive B-Cell Lymphomas (2013) (2)
Conflicts of interest, authorship, and disclosures in industry-related scientific publications. (2010) (2)
Resistance to Apoptosis in Human Myeloma Cell Lines Cell Adhesion Mediated Drug Resistance (CAM-DR): Role of Integrins and (2010) (2)
Lenalidomide and Risk of Acute Myeloid Leukemia (AML) Transformation Among Myelodysplastic Syndrome (MDS) Patients (2014) (2)
Cytogenetic findings in 122 cases of breast carcinoma (1991) (2)
Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center Experience. (2021) (2)
Severe combined immunodeficiency (SCID) mouse modeling of P-glycoprotein chemosensitization in multidrug-resistant human myeloma xenografts. (1995) (2)
Drug resistance in hematologic malignancies. (2005) (2)
Sequence of Therapy in Multiple Myeloma: Does It Matter? Retrospective Evaluation of Patients with Multiple Myeloma Who Have Received Bortezomib Followed by Lenalidomide or Vice Versa, (2011) (2)
The creation of an integrated health-information platform: building the framework to support personalized medicine. (2012) (2)
Advances in Brief Breast Cancer Resistance Protein Is Localized at the Plasma Membrane in Mitoxantrone-and Topotecan-resistant Cell Lines 1 (2000) (2)
Response Adapted Therapy Using Single Agent Lenalidomide in Older Adults with Newly Diagnosed Standard Risk Multiple Myeloma (2012) (2)
Cellular determinants of drug response provide new targets for cancer therapy (2000) (2)
microRNA expression proﬁle and identiﬁcation of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma (2010) (2)
Dexverapamil: A clinical approach to circumvention of multidrug resistance (1995) (1)
Radiologic abnormalities at the harvest site in patients undergoing bone marrow transplantation. (1992) (1)
Bone marrow stromal cells activate Stat3 and confer resistance to Bcr-Abl inhibitors in K562 CML cells (2008) (1)
The Bone Marrow Microenvironment: Novel Targets to Circumvent Minimal Residual Disease and Drug Resistance in Multiple Myeloma (2013) (1)
A Genomic Framework for Precision Radiation Therapy (2016) (1)
Adhesion of 8226 Myeloma Cell Lines Induces over Expression of HSP70 and its Inhibition Reverses CAM-DR and Acquired Drug Resistance in Multiple Myeloma. (2004) (1)
Outcomes Analysis of Doublets of Novel Agents with Corticosteroids Versus Regimens with 3 or More Agents for Multiple Myeloma (MM): A Retrospective Analysis (2011) (1)
Elimination of chemoresistant myeloma clonogenic cells from human bone marrow by monoclonal antibody and complement. (1990) (1)
Genetic and Environmental Determinants in Multiple Myeloma: Implications for Therapy (2012) (1)
B Cell Receptor (BCR) Signal Pathways Confer Microenvironment-Mediated Drug Resistance and Are Promising Therapeutic Targets for B Cell Lymphomas (2012) (1)
Identification of tumor biomarkers for sunitinib in advanced renal cell carcinoma (RCC). (2015) (1)
The development of novel targeted therapeutics for treatment of multiple myeloma research roundtable (2003) (1)
Abstract 435: Targeted exome sequencing to understand tumor progression and identify targeted therapies (2012) (1)
Large-Scale Evaluation of a Molecular Signature of Tumor Intrinsic Radiosensitivity in Solid Tumors (2014) (1)
Use of MicroRNA Expression Profiling to Identify Prognostic Subclasses in Mantle Cell Lymphoma: Mir-29 Family as New Prognostic Markers (2008) (1)
Bone Marrow Stroma (BMS) Prevents Apoptosis of Lymphoma Cells by Upregulation of BMS-Derived B-Cell Activating Factor (BAFF) and Activation of NF-kB. (2006) (1)
Bortezomib Enhances Melphalan Response by Altering Fanconi Anemia (FA)/BRCA Pathway Expression and Function. (2006) (1)
Optimizing Clinical Outcome and Toxicity in Lung Cancer Using a Genomic Marker of Radiosensitivity (2020) (1)
Abstract 5112: Proteomic investigation of melphalan resistance in multiple myeloma to support selection of combination therapy (2011) (1)
Analysis of the mechanisms of drug resistance in cancer by cDNA microarray (1999) (1)
Functional interactions between synthetic alkyl phospholipids and the ABC transporters P-glycoprotein, Ste-6, MRP, and Pgh 1. (1999) (1)
Hematopoietic progenitor cell content of bone marrow harvests: relative contributions of blood and bone marrow. (1994) (1)
Updated Results of the Phase II Study of Pegylated Liposomal Doxorubicin (PLD), Low Dose Dexamethasone (DEX) and Lenalidomide (LEN) In Patients with Newly Diagnosed (ND) Multiple Myeloma (MM) (2010) (1)
HSP70 Induces IL-6 in Stromal Cells and Stat-3 Activation in Myeloma Cells. (2004) (1)
Abstract LB-344: Senescence-related genes signature in high grade gliomas (2010) (0)
64: Interleukin-6 and hematopoietic soluble factors confers resistance to trail mediated apoptosis (2007) (0)
Treatments and Outcomes of Patients with Multiple Myeloma (MM) Older Than 75 Years of Age: A Single Institution Experience (2010) (0)
myeloma cells induced cytotoxicity in multiple - Ascorbic acid enhances arsenic trioxide (2013) (0)
β1-MEDIATED Adhesion to fibronectin protects cells from CD95-mediated apoptosis (2000) (0)
The phenomenon of multi drug resistance in non-Hodgkin ' s lymphoma (0)
Systems Biology Analysis Identifies Targetable Vulnerability Networks to Proteasome Inhibitors in Multiple Myeloma (2018) (0)
18P Systematic evaluation of published predictive gene expression signatures in pan-cancer patient cohorts treated with immune checkpoint inhibitors in a real-world setting (2022) (0)
Long term follow-up of edelfosine purging for autologous bone harrow transplantation (ABHT) in acute leukemia (1996) (0)
Phase II study of Fenretinide (N-[4-Hydroxyphenyllretinamide) in advanced breast cancer and melanoma (2001) (0)
MicroRNA-155 Is Regulated by the Transforming Growth Factor (cid:2) /Smad Pathway and Contributes to Epithelial Cell Plasticity by Targeting RhoA (cid:1) (2008) (0)
Characterization of Clonal Pre-B Cell Progenitors of Plasma Cells In Multiple Myeloma (2010) (0)
Correlation Between Tumor Intrinsic Radiosensitivity and Immune Activation in Solid Tumors (2014) (0)
Abstract 2097: microRNA profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma (2010) (0)
Environmental Mediated-Immune Resistance (EM-IR) to APO2L/TRAIL Mediated Apoptosis. (2007) (0)
Rational Drug Design: Proteasome Inhibitor Mediated Down-Regulation of the FA/BRCA Pathway Is Synergistic with PARP Inhibition in Myeloma Cell Lines (2011) (0)
of April 15 , 2017 . This information is current as Part by Regulating c-FLIP Apo 2 Ligand / TRAIL in Multiple Myeloma in Bone Marrow Stroma Confers Resistance (2008) (0)
Constitutive activation of stat signaling in myeloid leukemia cells is associated with resistance to apoptosis (2000) (0)
Ten Best Readings on New Anticancer Drugs (1999) (0)
Isolated local-regional failure after mastectomy and adriamycin-cytoxan chemotherapy: A role for postoperative radiotherapy in breast cancer (1987) (0)
Abstract B33: Project LINK: breaking new ground in fueling minority research experiences (2010) (0)
Glycosaminoglycan model glass substrates and cancer cell interactions (2006) (0)
Phase I Study of Bortezomib(Bz), Pegylated Doxorubicin(DOX) and Dexamethasone(dex); ( VDD) with Escalating Doses of Cyclophosphamide(Cy) in Patients with Newly Diagnosed Myeloma. (2009) (0)
Cell Lines Mechanisms of Doxorubicin Resistance in Two Human Tumor Pharmacological and Biological Evidence for Differing Updated (2006) (0)
Abstract 4809: Elucidating acquired drug resistance in multiple myeloma using expression proteomics and phosphorylation profiling (2012) (0)
Dna sequence amplification in a colon carcinoma cell line resistant to mitoxantrone (1986) (0)
Improved blood hematopoietic progenitor mobilization in myeloma patients following treatment with thalidomide (2000) (0)
Pharmacoproteomics Identifies PLK1 As Vulnerability for Aggressive B-Cell Lymphomas (2018) (0)
Abstract 1832: Large variations in clinical and ethical aspects of genomic sequencing initiatives: A Global Alliance for Genomics and Health (GA4GH) survey (2016) (0)
Microenvironment-Mediated Regulation of Micrornas In B-Lymphocytes as a Novel Mechanism for Terminal B-Cell Differentiation and Lymphomagenesis. (2010) (0)
Re-Constructing and Exploiting Transcriptional Regulatory Networks in Multiple Myeloma Drug Resistance (2019) (0)
Prognostic value of fas receptor and RB protein expression in patients with esophageal adenocarcinoma arising in Barrett's metaplasia (1998) (0)
mutation analysis Detection of Mutations in the Fas Antigen of Lymphoma Tumors by RT-PCR and Denaturing Gradient Gel Electrophoresis (2007) (0)
Targeting Mir-548m-HDAC6 Axis Circumvents Stroma- Mediated Drug Resistance (CAM-DR) and Clonogenicity in Non-Hodgkin B-Cell Lymphomas (2012) (0)
Plasticity by Targeting RhoA Pathway and Contributes to Epithelial Cell / Smad β Transforming Growth Factor MicroRNA-155 Is Regulated (2008) (0)
Part by Regulating c-FLIP Apo2 Ligand/TRAIL in Multiple Myeloma in Bone Marrow Stroma Confers Resistance to (2008) (0)
What have we learned from clinical MDR reversal studies?: 157 (1994) (0)
Lymphocytes and Isogenic Multidrug-Resistant Myeloma Cells: The Role of Cytotoxic T Cytokine-Based Tumor Cell Vaccine Is Equally Effective Against Parental (2010) (0)
Therapeutic modalities. (1997) (0)
Clinical cytogenetic correlations in solid tumors (1997) (0)
Enhancing enrollment using cohort surveillance for phase II biomarkers driven studies in patients with gastric/GEJ and pancreatic cancer. (2015) (0)
Abstract A67: An LC-MRM method to simultaneously measure abundance and activation of Src family tyrosine kinases in a B cell line model of IL-6 signaling (2010) (0)
Development and Characterization of a Melphalan-resistant Human Multiple Myeloma Cell Line 1 ' 2 (2006) (0)
Phase II study of pegylated liposomal doxorubicin (PLD), low-dose dexamethasone (DEX), and lenalidomide (LEN) in patients with newly diagnosed (ND) multiple myeloma (MM). (2009) (0)
Autologous Stem Cell Transplantation (ASCT) In Patients Aged ≥65 Years With Multiple Myeloma: Moffitt Cancer Center Experience (2009) (0)
A Phase II study of the safety, pharmacokinetics and efficacy of IncelTM (biricodar, VX-710) in combination with mitoxantrone (M) and prednisone (P) in advanced hormone refractory prostate cancer (HRPC) (1999) (0)
Therapeutic modalities. (1991) (0)
Abstract #5518: Bortezomib targets FANCD2 and enhances melphalan response in myeloma cells (2009) (0)
Microenvironment-Mediated Bim Down-Regulation through Induction of Microrna-181a Protects Cells From Apoptosis In Mantle-Cell and Other Non-Hodgkin B-Cell Lymphomas (2010) (0)
Hematopoietic Stroma Confers Resistance to Immune Control by TRAIL in Multiple Myeloma through Induction of FLIP. (2006) (0)
multiple myeloma ABCG2 expression, function, and promoter methylation in human (2013) (0)
Influence of Targeted Therapy in Redefining High-Risk Myeloma. (2008) (0)
Age Is the Strongest Independent Prognostic Factor in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation: Moffitt Cancer Center Experience (2008) (0)
Bortezomib Targets Stroma-Mediated APO2L/TRAIL Apoptosis Resistance in Multiple Myeloma. (2008) (0)
Abstract 4944: Combined treatment of BTK and PI3K inhibitors synergistically disrupts BCR-signaling, overcomes microenviroment-mediated survival and drug resistance in mantle cell lymphoma. (2013) (0)
MULTIDRUG RESISTANCE IN RHEUMATOID ARTHRITIS. AUTHORS' REPLY (1996) (0)
β1 Integrin Activation Via FN Adhesion Enhances IL-6 Response in Myeloma Cells. (2004) (0)
AProtectiveRolefortheHumanSMG-1KinaseagainstTumor NecrosisFactor--inducedApoptosis *□ (2008) (0)
The influence of the microenvironment in the pathogenesis and progression of human cancer (0)
Phenotypic Analysis Of Multiple Myeloma Cell Progenitors (2010) (0)
Bortezomib Reverts Stroma-Mediated Resistant to APO2L/TRAIL in Multiple Myeloma. (2009) (0)
A New Target in Multiple Myeloma: Inhibition of Notch Pathway Induces Apoptosis and Enhances Drug Sensitivity of Myeloma Cells In Vitro and In Vivo. (2006) (0)
469 Environmental mediated drug resistance (EMDR) in hematologic malignancies (2004) (0)
B 1 Integrin Adhesion Enhances IL-6–Mediated STAT3 Signaling in Myeloma Cells: Implications for Microenvironment Influence on Tumor Survival and Proliferation (2009) (0)
An ET-CURE Pilot Project Supporting Undergraduate Training in Cancer Research, Emerging Technology, and Health Disparities (2012) (0)
Crowdsourced High-Risk Classifiers for Multiple Myeloma Patients Commonly Identify PHF19 As a Robust Progression Biomarker (2019) (0)
A Systems Biology Approach to Identify Mechanisms of Therapy Resistance in Multiple Myeloma (2018) (0)
New Therapeutic Approaches to Myeloma (2004) (0)
NF-kB as a Regulator of FA/BRCA Gene Expression in Multiple Myeloma. (2007) (0)
A Novel Upregulation of Fanconi Anemia/BRCA DNA Repair Pathway Is Observed Upon Co-Culture of Bone Marrow Stroma with Multiple Myeloma Cell Lines: A Potential New Participant(s) in Environment Mediated Drug Resistance. (2009) (0)
MAPK/ERK1/2 kinase regulates the cytokine loop between Interleukin-6 (IL6) and Macrophage inflammatory protein alpha (MIP-1 a) in myeloma-stromal cell in-vitro model (2004) (0)
4 Cytogenetic and molecular genetic alterations associated with the development of anthracycline resistance (1987) (0)
Long–Term Survival of Allogeneic Transplantation(Allo SCT) In Selected Patients with Multiple Myeloma (MM): Disease Free Survival at Two Years May Indicate Long Term Survival (2009) (0)
Follicular Dendritic Cell (FDC)-Induced Microrna-Mediated up-Regulation of PRDM1 and Down-Regulation of BCL6 in Germinal Center B Lymphocytes: A Potential Mechanism for B-Cell Differentiation. (2009) (0)
Bortezomib Targets Stroma-Mediated APO2l/Trail Apoptosis Resistance In Multiple Myeloma (2009) (0)
Combined effects of Δ-9-THC and CBD in man (1975) (0)
Polyclonal origin of a primary breast carcinoma demonstrated by serial cytogenetic studies of a patient with a history of osteosarcoma (1993) (0)
184: Phase I Study of Bortezomib, (BTZ) followed by High-Dose Melphalan, (HD Mel) and BTZ as Conditioning Regimen for Tandem Peripheral Blood Stem Cell Transplants (TanPSCT) in Patients with Primary Refractory Multiple Myeloma (MM) and Plasma Cell Leukemia (PCL) (2008) (0)
Abstract IA27: An innovative approach to improve clinical trials using adaptive in silico design (2020) (0)
Sydney E. Salmon (2000) (0)
Proteasome inhibition in hematologic malignancies: clinical update and practical applications. (2004) (0)
Abstract B29: Training cancer researchers that are community advocates (2010) (0)
Prognostic and predictive signature discovery and validation in ovarian cancer utilizing the total-cancer-care (TCC) data warehouse. (2015) (0)
Abstract 5703: The immune cell state atlas analysis predicts therapeutic benefits with immune checkpoint inhibitors (2023) (0)
Phase I/II Trial of High-Dose Melphalan (M) and Topotecan (T) Followed by Autologous Stem Cell Rescue in Patients ≤ 60 and > 60 Years of Age with Multiple Myeloma (MM). (2007) (0)
Pharmacologic Modulation of Multidrug Resistance in Acute Leukemia: Results and Challenges (1996) (0)
New familial syndrome associated with t(7;10) diagnosed as a result of the cytogenetic study of a breast carcinoma (1991) (0)
Bortezomib-Induced Reversal of CAM-DR Phenotype in Myeloma Is Associated with AKT and ERK1/2 Signaling. (2004) (0)
Bortezomib Partially Overcomes TNF-Related Apoptosis Inducing ligand/Apo-2L (TRAIL/Apo-2L) Environment Mediated-Drug Resistance (EM-DR). (2004) (0)
Monitoring a Nuclear Factor- (cid:1) B Signature of Drug Resistance in Multiple Myeloma* (2011) (0)
Characterization of Clonotypic B Cell Progenitors in Bone Marrow of Multiple Myeloma Patients (2011) (0)
Influence of Fibronectin,(FN), Adhesion on Gene Expression Profiles, (GEP), of Isolated Patient Myeloma Cells. (2004) (0)
Advances in Brief Overexpression of a Dominant-Negative Signal Transducer and Activator of Transcription 3 Variant in Tumor Cells Leads to Production of Soluble Factors That Induce Apoptosis and Cell Cycle Arrest 1 (2001) (0)
Drug Resistance In The Treatment of Cancer: The reversal of multidrug resistance (1998) (0)
Abstract 4434: Selinexor and melphalan combination therapy for the treatment of multiple myeloma (2015) (0)
Ten Best Readings on Multiple Myeloma and Plasma Cell Dyscrasias: The ten best articles in the medical literature relating to multiple myelomaand plasma cell dyscrasias are reviewed here. (1998) (0)
Abstract 5504: FANCF over expression correlates with selected resistance to topoisomerase II inhibitors independent of other FA/BRCA DNA repair core complex constituents (2011) (0)
Cells in the Absence of P-Glycoprotein Overexpression Multidrug Resistance in Mitoxantrone-selected HL-60 Leukemia Updated (2006) (0)
Phospholipid remodeling via exogenous polyunsaturated fatty acid uptake modulates stress resistance in Vibrio cholerae (2020) (0)
Polymer model of cancer cell adhesion to glycosaminoglycan substrates using the radius of gyration (2009) (0)
Silencing c-Myc Using Myc Inhibitor JQ1 and EZH2 Inhibitor DZNep Blocks Converging Survival Signals in Aggressive B-Cell Lymphomas (2012) (0)
Pharmacokinetics (PK) and dynamics (PD) of the multidrug resistance (MDR) inhibitor GG918 in healthy volunteers (HVTS) (1996) (0)
GF120918 (GG918) tissue distribution in tumor bearing mice, favorable tumor retention of a potent P-glycoprotein blocker: 46 (1994) (0)
Multidrug Resistance and Its Circumvention in Acute Leukemia (1992) (0)
Mitoxantrone: a promising new chemotherapeutic agent. (1984) (0)
Selected Resistance to Topoisomerase II Inhibitors Correlates with the Over Expression of FANCF In a Fanconi Anemia/BRCA DNA Repair Pathway Independent Manner. (2010) (0)
Quantifying Inefficiencies in Empiric Radiation Dosing: The Clinical Cost of Ignoring Biological Heterogeneity (2019) (0)
Clinical correlations of chromosome change in human primary breast cancer (1990) (0)
Characterization of a R115777 Resistant Human Multiple Myeloma Cell Line with Cross-Resistance to PS-341. (2004) (0)
Analysis of the mechanisms of drug resistance in cancer by cDNA microarray (1999) (0)
Faculty Opinions recommendation of A "silent" polymorphism in the MDR1 gene changes substrate specificity. (2007) (0)
Biological basis of therapy: New molecular targets (2004) (0)
Unlocking the potential of real-world evidence (RWE) in oncology - technology- and informatics-enabled solutions for clinical care, precision medicine, and discovery (2019) (0)
The Labelling of Lipid and Protein Components in Isolated Central-Nervous- System Myelin with Dansyl Chloride (1977) (0)
Development and Characterization of a Melphalan-resistant Human Multiple Myeloma Cell Line1'2 (2006) (0)
Abstract 550: Transcriptional regulation of the Fanconi Anemia/BRCA DNA repair pathway component FANCD2 following co-culture of bone marrow stroma with multiple myeloma cell lines (2010) (0)
Enhanced DNA Repair Via Fanconi Anemia/BRCA Pathway Is Involved in Melphalan-Resistant Myeloma Cells. (2004) (0)
Reversal of multidrug resistance in hematologic malignancies with chemosensitizers: laboratory and clinical studies (1994) (0)
VerapumiI Reversal of Doxorubicin Resistance in Multidrug-resistant Human Myeloma Cells and Association with Drug Accumulation and DNA Damage1 (2006) (0)

This paper list is powered by the following services:

Other Resources About William S. Dalton

en.wikipedia.org

What Schools Are Affiliated With William S. Dalton?

William S. Dalton is affiliated with the following schools:

Image Attributions

Image Source for William S. Dalton